|
|
 |
|
 |
June 21, 2006
MDX Changes Company Name to Urodynamix Technologies Ltd. to Reflect New Focus on Urology Products and Trading Symbol to URO Effective June 21, 2006
For Immediate Release
Vancouver, BC - (June 21, 2006) Effective today MDX Medical Inc. (TSX.V: MDX) will change its name to Urodynamix Technologies Ltd. and the new trading symbol on the TSX-Venture will be URO. The company’s new website is www.urodynamix.com.
The new name reflects the company’s focus on urology, bladder diagnostics and monitoring solutions. The company’s products are designed for urologists, gynecologists, and primary care physicians who diagnose and treat conditions relating to the urinary tract, bladder and reproductive systems. These physicians are the primary care providers for sufferers of urinary incontinence, a condition that affects over 200 million people worldwide.
The new name, Urodynamix, is also based on urodynamic studies, which are a series of tests conducted on patients suffering from urinary incontinence to diagnose the cause. The current tests are invasive, painful, time consuming and require expensive equipment and consumables. Urodynamix is currently commercializing a new painless and non-invasive technology to replace these current tests. In addition, Urodynamix is developing its NIRS technology for other applications and clinical conditions.
Barry Allen, President and Chief Executive Officer, said, "Our new name, Urodynamix, reflects the Company’s focus on the attractive and growing markets in the areas of urodynamics, prostate screening and other applications relating to urology.”
On behalf of the Board,
“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.
Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein. Al though the Company believes that the expectations reflected in such forward-looking statements are reasonable; it can give no assurance that such expectations will prove correct.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Barry Allen
Email: ballen@urodynamix.com |
|  |
|
